Aggressive B-cell non-Hodgkin lymphoma

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…

This phase II trial tests whether combining pembrolizumab (Keytruda) and tazemetostat can help prevent aggressive B-cell lymphoma from returning after patients have already received a stem cell transplant or CAR-T cell therapy. The study enrolls 32 adults and will measure how lon…

This phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treat…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…

This phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…

This early-stage study tests whether adding either iberdomide or CC-99282 to standard chemotherapy (R-CHOP) can safely treat people with untreated aggressive B-cell lymphoma. About 224 adults will take part. The main goals are to find the best dose and check for side effects, whi…

This study tests whether a very low dose of radiation (4 Gy) can control slow-growing B-cell lymphoma in the eye socket. About 50 adults with stage I-IV indolent lymphoma or mantle cell lymphoma will receive this targeted treatment. The goal is to shrink or stop the cancer while …

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…

This study tests an experimental drug, odronextamab, in people with aggressive B-cell non-Hodgkin lymphoma that has come back or no longer responds to treatment. About 216 participants will receive either the new drug or standard therapy to compare safety, effectiveness, and qual…

This study tests whether adding the targeted drug rituximab to standard chemotherapy can improve outcomes for children and teens with aggressive B-cell lymphoma or leukemia. About 650 participants from Europe will receive different treatment schedules to find the best balance of …

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This phase 2 trial tests a chemotherapy-light combination of three drugs—rituximab, polatuzumab vedotin, and glofitamab—in 125 patients over 60 with aggressive B-cell lymphoma who cannot tolerate full-dose standard chemo. The goal is to see if this gentler approach can control th…

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This phase 2 trial is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. The study enrolls 30 patients with various subtypes of the disease. The main g…

This phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…

This early-phase study tests a combination of five drugs (VIPOR) in 14 adults with aggressive B-cell lymphoma that has spread to the brain or spinal cord. The main goal is to see if the treatment is safe enough for patients to complete at least two 21-day cycles without serious s…

This was a phase I trial testing a new drug called CB-5339 in people with advanced solid tumors or lymphomas. The drug was designed to block certain enzymes that cancer cells need to grow. However, the study was withdrawn before enrolling any participants, so no results or safety…

This pilot study aimed to see if it is possible to use neuropsychological tests to measure thinking, memory, and emotional health in adults who received CAR-T therapy for aggressive lymphoma at least six months earlier. The study was withdrawn before enrolling any participants, s…

This study looks at whether a blood test can spot signs of lymphoma coming back after chemotherapy, possibly earlier than regular CT scans. About 500 adults with aggressive B-cell Non-Hodgkin lymphoma will give blood samples after treatment. The goal is to see if this test could …

This study follows 500 adults aged 18-65 who completed chemotherapy for certain cancers and are in remission. Researchers will check for 19 possible late side effects over 5 years, including heart, lung, and hormone problems. The goal is to catch these issues early and connect pa…